poisar

Stocks · News reference

8-K filing — NewAmsterdam Pharma Co N.V. (NAMSW)

Jul 22, 2026, 8:05 PMSEC EDGAR

Filed: 2026-07-22 AccNo: 0001193125-26-312390 Size: 202 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NAMSW
Source
edgar
Observed
Jul 22, 2026, 8:05 PM
Checked
Jul 22, 2026, 8:05 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jun 3, 2026, 12:00 PMNewamsterdam Pharma Company N.V.

    NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

    NewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-world evidence on statin intolerance. The company has also granted European commercialization rights to the Menarini Group.

    Read original at globenewswire-inc
    NAMSNAMSW